Qualifying & Developing VEGF Binding Assay using an iQue® Screener PLUS

25th May 2018

Category: Bioanalytical

By: Ben Tyrrell - Scientist, Katie Chapple - Scientist,

The iQue® Screener PLUS, by Intellicyt (part of the Sartorius Group), is used at Sartorius Stedim BioOutsource to achieve a faster assay throughput and deliver an air-gap-deliminated flow of samples to the detectors.

Bevacizumab is a humanized monoclonal antibody (mAb) which mediates its activity through a high affinity binding to VEGF (vascular endothelial growth factor). VEGF is a signalling protein which is involved in the initiation of vasculogenesis and angiogenesis of blood vessels. Due to the reliance of solid tumours on efficient angiogenesis to grow beyond a few mm3 in volume, bevacizumab is used as a combination therapy for a number of malignancies.

By using the latest flow cytometry technology we were able to create an easy-to-use, highly reproducible, and time saving assay specific to bevacizumab. This included using a florescence readout on the iQue® Screener PLUS to quantify the antibody binding, and its specificity was assessed using a range of IgG1 isotype controls.

To find out more about the development method used to qualify this assay, download our scientific poster.

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.